Skip to main content
Fig. 1 | BMC Cardiovascular Disorders

Fig. 1

From: Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

Fig. 1

Study design for the Phase 2 study (A) and immuno-PET study (B). *Blood SAP depletion could extend beyond Days –2 and –1. Note: for the Phase 2 study the start of anti-SAP monoclonal antibody treatment was denoted as Day 1, whereas for the immuno-PET study the start of miridesap treatment was denoted as Day 1. CMR cardiac magnetic resonance, ECHO echocardiogram, IV intravenous, MRI magnetic resonance imaging, PET positron emission tomography, SAP serum amyloid P component, SC subcutaneous

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us